Randomized, Multicenter, Prospective Two-Arm, Open-Label Phase II Study to Investigate the Efficacy and Safety of Two ZK219477 i.v. Infusions (3-Hour Infusion of 16mg/m2 Versus 0.5-Hour Infusion of 16 mg/m2) in Patients With Recurrent Ovarian Cancer Progressing During, or Within 6 Months of the End of Platinum-Based Chemotherapy
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Proportion of responders
Bayer Study Director
United Kingdom: Medicines and Healthcare Products Regulatory Agency